Fampridine treatment in multiple sclerosis patients

The results of a beautifully designed and executed trial, testing the effects of fampridine on internuclear ophthalmoparesis (INO) in multiple sclerosis (MS), are now available. In conclusion, fampridine improves saccadic eye movements due to INO in MS. Treatment response to fampridine may gauge patient selection for inclusion to remyelination strategies in MS using saccadic eye movements as primary outcome measure.


Full open article below:


https://www.ncbi.nlm.nih.gov/pubmed/30756475

Recent Posts

See All

Outsourced trials - outsized problems

A good summary of the main issue: “The pharmaceutical industry needs to engage properly with the regulators and stop interpreting what they believe is expected of them”. “Those of us who still run aca

CONTACT US

The Netherlands (HQ)     Romania

Parkstraat 83, 2514 JG        17 C.A. Rosetti, 2nd District

The Hague                          Bucharest

P: +31 (0) 703 538 154        + 40 (0) 21 527 03 51

F: +31 (0) 703 538 333        + 40 (0) 21 527 03 10

                         

                          office@saberg.org

                           www.saberg.org

Saberg Clinical Research is a ​​​​trade name of InterEuropa Clinical Research BV

 © 2015 Goosh 

  • Twitter Saberg Clinical Research
  • LinkedIn Saberg Clinical Research